Summary:
«Boundless Bio’s research has uncovered a previously unknown driver of cancer growth and drug resistance. With $105 million in Series B financing, the biotech is on a path to bring to the clinic small molecules that address this target, called extrachromosomal DNA.»
Article written by FRANK VINLUAN
28|04|2021
Source:
MedCity News
https://medcitynews.com/2021/04/startup-boundless-bio-brings-in-105m-to-break-the-circle-behind-cancer-growth/?rf=1